Circulating plasmablasts in children with steroid-sensitive nephrotic syndrome.
B cells
Immunosuppression
Pediatric nephrology
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
09
07
2021
accepted:
13
08
2021
revised:
07
08
2021
pubmed:
19
10
2021
medline:
16
4
2022
entrez:
18
10
2021
Statut:
ppublish
Résumé
The therapeutic efficacy of B cell-depleting anti-CD20 treatment in both pediatric and adult steroid-sensitive nephrotic syndromes (SSNS) suggests that B cells play a pathogenic role in the disease. In adults with minimal change disease (MCD), only circulating plasmablasts are increased during the active phase of the disease, among B cell subsets. These cells have not been studied yet in children with SSNS. We retrospectively quantified by flow cytometry analysis circulating plasmablasts in 107 pediatric patients with SSNS (51 at disease onset, 27 during relapse, and 29 in remission). Data were compared with an equal number of age- and sex-matched healthy donors (HD). Circulating plasmablast levels, expressed as percentage of total CD19 The B cell phenotype of children with SSNS differs from that of adults with MCD. This may justify different therapeutic approaches.
Sections du résumé
BACKGROUND
The therapeutic efficacy of B cell-depleting anti-CD20 treatment in both pediatric and adult steroid-sensitive nephrotic syndromes (SSNS) suggests that B cells play a pathogenic role in the disease. In adults with minimal change disease (MCD), only circulating plasmablasts are increased during the active phase of the disease, among B cell subsets. These cells have not been studied yet in children with SSNS.
METHODS
We retrospectively quantified by flow cytometry analysis circulating plasmablasts in 107 pediatric patients with SSNS (51 at disease onset, 27 during relapse, and 29 in remission). Data were compared with an equal number of age- and sex-matched healthy donors (HD).
RESULTS
Circulating plasmablast levels, expressed as percentage of total CD19
CONCLUSIONS
The B cell phenotype of children with SSNS differs from that of adults with MCD. This may justify different therapeutic approaches.
Identifiants
pubmed: 34661744
doi: 10.1007/s00467-021-05273-8
pii: 10.1007/s00467-021-05273-8
doi:
Substances chimiques
Prednisone
VB0R961HZT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
455-459Informations de copyright
© 2021. The Author(s), under exclusive licence to International Pediatric Nephrology Association.
Références
Ravani P, Bonanni A, Rossi R, Caridi G, Ghiggeri GM (2016) Anti-CD20 Antibodies for idiopathic nephrotic syndrome in children. Clin J Am Soc Nephrol 11:710–720. https://doi.org/10.2215/CJN.08500815
doi: 10.2215/CJN.08500815
pubmed: 26585985
Gauckler P, Shin JI, Alberici F, Audard V, Bruchfeld A, Busch M, Cheung CK, Crnogorac M, Delbarba E, Eller K, Faguer S, Galesic K, Griffin S, van den Hoogen MWF, Hrušková Z, Jeyabalan A, Karras A, King C, Kohli HS, Mayer G, Maas R, Muto M, Moiseev S, Odler B, Pepper RJ, Quintana LF, Radhakrishnan J, Ramachandran R, Salama AD, Schönermarck U, Segelmark M, Smith L, Tesař V, Wetzels J, Willcocks L, Windpessl M, Zand L, Zonozi R, Kronbichler A; RITERM study group (2020) Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - what is known and what is still unknown? Autoimmun Rev 19:102671. https://doi.org/10.1016/j.autrev.2020.102671
doi: 10.1016/j.autrev.2020.102671
pubmed: 32942039
Lapillonne H, Leclerc A, Ulinski T, Balu L, Garnier A, Dereuddre-Bosquet N, Watier H, Schlageter MH, Deschenes G (2008) Stem cell mobilization in idiopathic steroid-sensitive nephrotic syndrome. Pediatr Nephrol 23:1251–1256. https://doi.org/10.1007/s00467-008-0793-2
doi: 10.1007/s00467-008-0793-2
pubmed: 18458957
Colucci M, Carsetti R, Cascioli S, Serafinelli J, Emma F, Vivarelli M (2019) B cell phenotype in pediatric idiopathic nephrotic syndrome. Pediatr Nephrol 34:177–181. https://doi.org/10.1007/s00467-018-4095-z
doi: 10.1007/s00467-018-4095-z
pubmed: 30267238
Ling C, Wang X, Chen Z, Fan J, Meng Q, Zhou N, Sun Q, Hua L, Gui J, Liu X (2019) Altered b-lymphocyte homeostasis in idiopathic nephrotic syndrome. Front Pediatr 7:377. https://doi.org/10.3389/fped.2019.00377
doi: 10.3389/fped.2019.00377
pubmed: 31649905
pmcid: 6794445
Oniszczuk J, Beldi-Ferchiou A, Audureau E, Azzaoui I, Molinier-Frenkel V, Frontera V, Karras A, Moktefi A, Pillebout E, Zaidan M, El Karoui K, Delfau-Larue MH, Hénique C, Ollero M, Sahali D, Mahévas M, Audard V (2021) Circulating plasmablasts and high level of BAFF are hallmarks of minimal change nephrotic syndrome in adults. Nephrol Dial Transplant 36:609–617. https://doi.org/10.1093/ndt/gfaa279
doi: 10.1093/ndt/gfaa279
pubmed: 33241414
Schrezenmeier E, Jayne D, Dörner T (2018) Targeting b cells and plasma cells in glomerular diseases: translational perspectives. J Am Soc Nephrol 29:741–758. https://doi.org/10.1681/ASN.2017040367
doi: 10.1681/ASN.2017040367
pubmed: 29326157
pmcid: 5827591
Vivarelli M, Massella L, Ruggiero B, Emma F (2017) Minimal change disease. Clin J Am Soc Nephrol 12:332–345. https://doi.org/10.2215/CJN.05000516
doi: 10.2215/CJN.05000516
pubmed: 27940460
Colucci M, Carsetti R, Cascioli S, Casiraghi F, Perna A, Rava L, Ruggiero B, Emma F, Vivarelli M (2016) B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol 27:1811–1822. https://doi.org/10.1681/ASN.2015050523
doi: 10.1681/ASN.2015050523
pubmed: 26567244
Bhatia D, Sinha A, Hari P, Sopory S et al (2018) Rituximab modulates T- and B-lymphocyte subsets and urinary CD80 excretion in patients with steroid-dependent nephrotic syndrome. Pediatr Res 84:520–526. https://doi.org/10.1038/s41390-018-0088-7
doi: 10.1038/s41390-018-0088-7
pubmed: 29983411
De Bruyne R, Bogaert D, De Ruyck N, Lambrecht BN, Van Winckel M, Gevaert P, Dullaers M (2015) Calcineurin inhibitors dampen humoral immunity by acting directly on naive B cells. Clin Exp Immunol 180:542–550. https://doi.org/10.1111/cei.12604
doi: 10.1111/cei.12604
pubmed: 25682989
pmcid: 4449782
Smulski CR, Eibel H (2018) BAFF and BAFF-receptor in B cell selection and survival. Front Immunol 9:2285. https://doi.org/10.3389/fimmu.2018.02285
doi: 10.3389/fimmu.2018.02285
pubmed: 30349534
pmcid: 6186824
Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA; BLISS-52 Study Group (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377:721–731. https://doi.org/10.1016/S0140-6736(10)61354-2
doi: 10.1016/S0140-6736(10)61354-2
Barrett C, Willcocks LC, Jones RB, Tarzi RM, Henderson RB, Cai G, Gisbert SI, Belson AS, Savage CO (2020) Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy. Nephrol Dial Transplant 35:599–606. https://doi.org/10.1093/ndt/gfz086
doi: 10.1093/ndt/gfz086
pubmed: 31243451
Vivarelli M, Colucci M, Gargiulo A, Bettini C, Emma F (2021) Belimumab for the treatment of children with frequently relapsing nephrotic syndrome: the BELNEPH study. Pediatr Nephrol. https://doi.org/10.1007/s00467-021-05175-9
doi: 10.1007/s00467-021-05175-9
pubmed: 34661744